Growth Factors (Blood And Tissue)

Published by: Global Industry Analysts

Published: Feb. 1, 2006 - 274 Pages

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. Introduction

Growth Factors: A Preface

Growth Factors: Their Role and Related Applications

Growth Factors: Adding a New Dimension

Growth Factors: Classification Based on Activity

Recent Trends & Developments

Recombinant Human Erythropoietin: Gradually Gaining Dominance

2. Market Overview

Analysis by Region

US: The Single Largest Market

Growth Factors Market in Europe

Market for Growth Factors in Rest of World

Table 1: World Market for Growth Factors (2000-2010): Geographic Regions Ranked by CAGR-Europe, US, Japan, and Rest of World (includes corresponding Graph/Chart)

Analysis by Growth Factor Type

EPO-The Lead ‘Factor’

Leading EPO Drugs Worldwide

Table 2: World Recombinant Protein Market (2003-2005): Percentage Breakdown of Value Sales by Company for Amgen, Johnson & Johnson, Novo Nordisk, Roche, and Schering Plough (includes corresponding Graph/Chart)

Market Comparison of Erythropoietin-Based Drugs in America and European Union: Classification Based on Key Parameters

3. Market Dynamics

Dethroning the Leaders

Expiration of Patents Fuels Competition and Sales

India-At the Center Stage

Side Effects-Still a Concern

CDER-A Regulatory Review Authority for Growth Factors

4. Outlook

Innovative Delivery System Shows Potential for Accelerating Use of Growth Factors

Cytokines-Vital Growth Propellers for the Future of New Drugs

Brain Derived Neurotrophic Factor (BDNF) Finds Increased Application

Age-Related Diseases-Their Influence on Effective Therapies

Copaxone Finds Novel Applications

Mimetic Growth Factors-Exhibiting Promising Potential

5. Industry Issues

Development of Cost Effective Methods-Need of the Hour

Influence of Neurotrophic Factors on Brain Cell Development

Combination of Interferons and Ribavirin Develops More Anemia Cases

6. Competitive Trends

RegeneRx Focuses on Wound Healing Market

DRL to Initiate Program to Propel its Biogenerics Business

7. Growth Factors-An Overview

Blood Growth Factors

Erythropoietins

Types of Erythropoietins

Epoetin

Darbepoetin

Aranesp®

Aranesp Vs Other EPOs

Recombinant human EPO (rHuEPO)

Table 3: World Market for Erythropoietins (2000-2010): Geographic Regions Ranked by CAGR-Europe, US, Rest of World and Japan (includes corresponding Graph/Chart)

Colony Stimulating Factors

Granulocyte-Colony Stimulating Factor

Granulocyte Macrophage-Colony Stimulating Factor

Other Colony Stimulating Factors

Macrophage Colony Stimulating Factor (M-CSF)

Key Functions of M-CSF

Side-Effects of Colony-Stimulating Factors

Table 4: World Market for Colony Stimulating Factors (2000-2010): Geographic Regions Ranked by CAGR-Europe, Japan, US, and Rest of World (includes corresponding Graph/Chart)

Interferons

Types of Interferons

Interferon-gamma

1a and 1b: Two Key Biochemical Forms of Interferon-ß

PEG-Intron

Types of Interferons

Table 5: World Market for Interferons as Blood Growth Factors (2000-2010): Geographic Regions Ranked by CAGR-US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart)

Interleukins

Types of Interleukins

Table 6: World Market for Interleukins as Blood Growth Factors (2000-2010): Geographic Regions Ranked by CAGR-Europe, Rest of World, Japan, and US (includes corresponding Graph/Chart)

Tissue Growth Factors

Wound Healing Growth Factors

Neurotrophic Growth Factors

Nerve Growth Factor

Vascular Endothelial Growth Factor (VEGF)

Fibroblast Growth Factor (FGF)

Insulin-Like Growth Factor-I (IGF-I)

Insulin-Like Growth Factor-II (IGF-II)

Tissue Growth Factors: Classification Based on Key Source and Principal Activity

Platelet-Derived Growth Factors in Wound Healing

Thrombopoietin (TPO)

Table 7: World Market for Tissue Growth Factors (2000-2010): Geographic Regions Ranked by CAGR-US, Europe, Japan, and Rest of World (includes corresponding Graph/Chart)

Growth Factors: Their Mode of Action in Tissue Repair

Angiogenesis: Their Role in Wound Healing

Angiogenesis As an Alternative for Cardiac Stents

Applications of Growth Factors

Growth Factors: Application by Compound and Supplier

Growth Factors: Indicated Applications by Site/Course of Action

8. Research and Development Highlights

Maxygen Updates on Factor VII Program

Evaluation of Extended Dosing Schedule of PROCRIT®

PROCRIT®-A Better Option

Nerve Growth Factor Shows Promising Potential Against Diabetes

Cytokines and GM-CSF Found to be Closely Interlinked

GM-CSF Enhances Rate of Survival in Neonates

rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients

rG-CSF-Their Influence on Preterm Infants with Sepsis

Serum Macrophage Colony Stimulating Growth Factors Associated with Thrombocyte and Monocyte

Src Pathway Inactivation in Kit Impairs Blood Cell Growth and Proliferation

Cole Eye Institute Offers TIMP-3 Mechanism for Preventing Abnormal Growth of Blood Vessels

Effect of Brain Derived Neurotrophic Factor on Retinal Cells

Orcel™ Exhibits High Growth Factor for Wound Healing and Cardiovascular Applications

Drug Combination of Macrophage Colony Stimulating Factor Shows Successful Tolerance Levels

Neotrofin ™ Triggers Neurotrophic Factors

G-CSF Shows Capability for Promoting Neutrophil Production

Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates Wound Healing Process

Hepatocyte Growth Factors-Exhibiting Dual Role

Cortex Pharmaceuticals Ampakines® Promotes Expression of Neurotrophin

Granulocyte Colony Stimulating Factor Finds Application in Treating Neonates

Cerebrolysin Promotes Cognition

9. Breakthroughs-A Review

Novel Set of Human Cytokines Unveiled

IGFBP-3 and its Potential to Ward Off Gastric Cancer

Bone Morphogenic Proteins Show Potential for Musculoskeletal Regeneration

Growth Factors-Their Role in Preventing Heart Stroke

Growth Factor Proteins Shows Promising Results for Treating Cancer

Neurotrophic Growth Factor Primarily Responsible for Loss of Vision

Redox-Active Grape Seed Exhibits Favorable Properties for Dermal Wound Healing

Role of Brain-Derived Neurotrophic Factor on Memory

Nerve Growth Factor Found to Enhance Barium Current and Insulin Secretion

Lipid Peroxidation May be Associated with Wound Healing

Genentech Inc Unveils Molecule for Stimulating Growth of Blood Vessels

Connective Tissue Growth Factor Found to Promote Lung Fibroblast

Influence of Insulin-Like Growth Factor on Growth

Regeneron Discovers Angiopoietins Targeted at Blood Vessel Growth and Repair

Environment and Insulin-Like Growth Factors Stimulate Risk of Cancer

Cocktail of Neurotrophic Factors Promotes Regeneration of Torn Nerves

Growth Factors Administration to Stimulate Tissue Repair

Cytokine-Their Role in Combating Hepatitis C Virus

Axokine® Yields Favorable Results Against Obesity

Cell Genesys Unveils GDNF Gene Therapy Targeted Against Parkinson’s Disease

10. Product Introduction

Ventria Bioscience Introduces Lacromin™

11. Product Launches in Recent Past

Wockhardt Introduces Wepox Recombinant Erythropoietin Drug

Shanta Biotechnics Unveils Shanferon

SkinMedica Unveils TNS Recovery Complex™ Gel

CellGenix Unveils Cytokines for Cell Applications

Cel-Sci Corporation Develops Multikine

Wockhardt Limited Unveils EPOX™

12. Recent Industry Activity

GeneMedix Collaborates with CJ Corp.

FzioMed and USC Enter into Licensing Agreement for Oligopeptides

Tercica Receives FDA Approval For Increlex

AnGes MG Enters Into An Agreement with Vical

Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA

Dragon Pharmaceuticals Acquires Oriental Wave

Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series

Amrad and Ludwig Institute Jointly Focus on the Development of VEGF-B

GeneMedix Restructures Business

pSivida Limited Collaborates with Ian Wark Research Institute

Amgen Acquires Tularik

BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S™

DPI Receives Approvals for Erythropoietin in Three New Markets

Chugai and Roche Expand Drug Research Synergies

Dragon Pharmaceuticals to Construct New Production Facility

FibroGen Signs Contract with Yamanouchi for Licensing EPO Small Molecule

Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine

Maxygen and Rentschler Enter into a Contract for G-CSF

Maxygen Signs Agreement with Biovitrum for Manufacturing Beta Interferon

Dragon Pharmaceuticals Signs Agreement with Zhongkai

Dragon Pharmaceuticals Enters into Definitive Agreement with Oriental Wave

Zymogenetics Bags US FDA Clearance

Ceregene Bags Patent

13. Strategic Corporate Developments in Recent Past

AME Enters into Third Collaboration with Eli Lilly and Company

ViaCell Enters into Licensing Agreement and Collaboration with Amgen

Ceregene Enters into Licensing Agreement with Genentech

BIOPHARM GmbH Enters into Licensing Contract with DePuy

Maxygen Enters into a Deal with Roche Holding

Dragon Pharmaceuticals Bags Market Approval from Chinese SDA

GeneMedix Signs Agreement with SkyePharma

Neurotech Enters into Licensing Agreement with Amgen

Ceregene Enters into a Licensing Agreement with Washington University

NeoTherapeutics Receives US Patent for Stimulating Neuritogenesis

BioSET Bags Global Exclusive License for Novel Growth Factor Technology

ViaCell Acquires Cerebrotec

Fibrogen Collaborates with Sankyo

Prescient NeuroPharma Collaborates with SRIB

Dragon Pharmaceuticals Signs Agreement with Renapharm AB and Transworld

Baxter Bags Exclusive Worldwide Rights for Epoetin Omega

Ortec International Bags FDA PMA for OrCel

GeneMedix Bags Chinese SDA Approval

NsGene Collaborates with ARIAD Pharmaceuticals

Regeneron Enters into Agreement with Emisphere Technologies

NsGene A/S Signs Agreement with Biogen Inc

NTB Enters into BioInformatics Outsourcing Agreement with HSC

14. Focus on Select Global Players

Amgen (US)

Biomimetic Pharmaceuticals Inc. (US)

Biopharm GmbH (Germany)

Bolder Biotechnology (US)

Boston Life Sciences, Inc. (US)

Cambrex (US)

Ceregene Inc. (US)

Dragon Pharmaceuticals, Inc. (Canada)

FibroGen Inc. (US)

FzioMed Inc. (US)

GeneMedix Plc. (UK)

Insmed Inc. (US)

Johnson & Johnson (US)

Janssen-Ortho Inc. (Canada)

Maxygen, Inc. (US)

NsGene A/S (Denmark)

PeproTech Inc. (US)

Rentschler Biotechnologie GmbH (Germany)

Roche (Switzerland)

Chugai Pharmaceutical Co. Ltd. (Japan)

Genentech Inc. (US)

Scil Proteins (Germany)

Wockhardt Ltd. (India)

15. Global Market Perspective

Table 8: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region-US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 9: World 10-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region-Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 10: World Recent Past, Current & Future Analysis for Blood Growth Factors by Geographic Region-US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 11: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type-Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 12: World 10-Year Perspective for Blood Growth Factors by Geographic Region-Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 13: World 10-Year Perspective for Blood Growth Factors by Type-Percentage Breakdown of Dollar Sales for Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 14: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region-US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 15: World 10-Year Perspective for Erythropoietins by Geographic Region-Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 16: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region-US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 17: World 10-Year Perspective for Colony Stimulating Factors by Geographic Region-Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 18: World Recent Past, Current & Future Analysis for Interferons as Blood Growth Factors by Geographic Region-US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 19: World 10-Year Perspective for Interferons as Blood Growth Factors by Geographic Region-Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 20: World Recent Past, Current & Future Analysis for Interleukins as Blood Growth Factors by Geographic Region-US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 21: World 10-Year Perspective for Interleukins as Blood Growth Factors by Geographic Region-Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 22: World Recent Past, Current & Future Analysis for Tissue Growth Factors by Geographic Region-US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 23: World 10-Year Perspective for Tissue Growth Factors by Geographic Region-Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

A. Market Analysis

Current and Future Analysis

EPO Market Scenario

Key Market Driver for EPO

Leading EPO Drugs in the US

Table 24: Erythropoietin Market in the US (2002-2004): Percentage Breakdown of Value Sales by Company (includes corresponding Graph/Chart)

Recent Industry Activity

Strategic Corporate Developments in Recent Past

Product Launches in Recent Past

Key Players

B. Market Analytics

Table 25: US Recent Past, Current & Future Analysis for Growth Factors by Type-Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 26: US 10-Year Perspective for Growth Factors by Type-Percentage Breakdown of Dollar Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

2. Japan

A. Market Analysis

Current and Future Analysis

Erythropoietin Market: Competitive Scenario

Leading EPO Drugs in Japan

Table 27: Erythropoietin Market in Japan (2002-2004): Percentage Breakdown of Value Sales by Company for Roche/ Chugai and Sankyo

Market Scenario for Biotech Products

Biotech Market Backed by Public Assistance

Recent Industry Activity

Chugai Pharmaceutical Co. Ltd.-A Key Player

B. Market Analytics

Table 28: Japanese Recent Past, Current & Future Analysis for Growth Factors by Type-Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 29: Japanese 10-Year Perspective for Growth Factors by Type-Percentage Breakdown of Dollar Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

3. Europe

A. Market Analysis

Current and Future Analysis

Erythropoietin Market Scenario in the Recent Past

Leading EPO Drugs in Europe

Table 30: Erythropoietin Market in Europe (2002-2004): Percentage Breakdown of Value Sales by Company for Johnson & Johnson, Roche and Amgen (includes corresponding Graph/Chart)

Recent Industry Activity

Strategic Developments in Recent Past

Product Launch in Recent Past

Key Players

B. Market Analytics

Table 31: European Recent Past, Current & Future Analysis for Growth Factors by Type-Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 32: European 10-Year Perspective for Growth Factors by Type-Percentage Breakdown of Dollar Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

4. Rest of World

A. Market Analysis

Current and Future Analysis

Indian Erythropoietin Market-Global Companies Focusing on India

Recent Industry Activity

Strategic Developments in Recent Past

Product Launches in Recent Past

Key Players

B. Market Analytics

Table 33: Rest of World Recent Past, Current & Future Analysis for Growth Factors by Type-Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 34: Rest of World 10-Year Perspective for Growth Factors by Type-Percentage Breakdown of Dollar Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for 2000, 2005 & 2010 (includes corresponding Graph/Chart)

IV. COMPETITION

1. Amgen, Inc. (USA)

Table 35: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)

Table 36: Half Yearly Sales Analysis by Geographic Region: 2004-2005 (Q1) (In US$ million)

Table 37: Annual Sales Analysis: 2003-2004 (In US$ million)

Table 38: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million)

2. Amrad Corporation Limited (Australia)

3. BD Biosciences (USA)

4. Berlex Laboratories, Inc. (USA)

5. BioMimetic Pharmaceuticals, Inc. (USA)

6. Biopharm GMBH (Germany)

7. Bio Surface Engineering Technologies, Inc. (USA)

8. Bolder BioTechnology, Inc. (USA)

9. Boston Life Sciences, Inc. (USA)

10. Cambrex Corporation (USA)

Table 39: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)

Table 40: Annual Sales Analysis: 2003-2004 (In US$ million)

11. Ceregene, Inc. (USA)

12. Chiron Corporation (USA)

Table 41: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)

Table 42: Annual Sales Analysis: 2003-2004 (In US$ million)

Table 43: Annual Sales Analysis by Business Segment: 2003-2004 (In US$ million)

Table 44: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ million)

13. Cortex Biochem, Inc. (USA)

14. Curis, Inc. (USA)

15. Cytomedix, Inc. (USA)

16. Dragon Pharmaceuticals, Inc. (Canada)

Table 45: Annual Sales Analysis: 2003-2004 (In US$ million)

Table 46: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million)

17. F. Hoffmann-La Roche Ltd. (Switzerland)

Table 47: Half Yearly Sales Analysis: 2004-2005 (H1) (In CHF million)

Table 48: Annual Sales Analysis: 2003-2004 (In CHF million)

Table 49: Annual Sales Analysis by Division: 2003-2004 (In CHF million)

Chugai Pharmaceutical Co., Ltd. (Japan)

18. Genentech, Inc. (USA)

Table 50: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)

Table 51: Annual Sales Analysis: 2003-2004 (In US$ million)

Table 52: Annual Sales Analysis by Product: 2003-2004 (In US$ million)

19. FibroGen, Inc. (USA)

20. Genemedix PLC (UK)

21. GenVec, Inc. (USA)

Table 53: Half-Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)

Table 54: Half-Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)

Table 55: Annual Sales Analysis: 2003-2004 (In US$ million)

22. Insmed, Inc. (USA)

Table 56: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ thousand)

Table 57: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ thousand)

Table 58: Annual Sales Analysis: 2003-2004 (In US$ thousand)

Table 59: Quarterly Sales Analysis: 2003-2004 (In US$ thousand)

23. Invitrogen Corporation (USA)

Table 60: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)

Table 61: Annual Sales Analysis: 2003-2004 (In US$ million)

Table 62: Annual Sales Analysis by Segment: 2003-2004 (In US$ million)

24. Johnson & Johnson (USA)

Table 63: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ billion)

Table 64: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ billion)

Table 65: Half Yearly Sales Analysis by Geographic Region: 2004-2005 (H1) (In US$ billion)

Table 66: Annual Sales Analysis: 2003-2004 (In US$ billion)

Table 67: Quarterly Sales Analysis: 2003-2004 (In US$ billion)

Table 68: Annual Sales Analysis by Segment: 2003-2004 (In US$ billion)

Table 69: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ billion)

Janssen-Ortho, Inc. (Canada)

Ortho Biotech Products LP (USA)

25. Maxygen, Inc. (USA)

Table 70: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)

Table 71: Annual Sales Analysis by Segment: 2004-2005 (H1) (In US$ million)

Table 72: Annual Sales Analysis: 2003-2004 (In US$ million)

Table 73: Annual Sales Analysis by Segment: 2003-2004 (In US$ million)

Table 74: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million)

26. NsGene A/S (Denmark)

27. Ortec International, Inc. (USA)

28. Orthologic Corporation (USA)

29. PeproTech, Inc. (USA)

CytoLab Ltd. (Israel)

30. Prospec-Tany Technogene, Ltd. (Israel)

31. QED Bioscience, Inc. (USA)

32. R&D Systems, Inc. (USA)

33. Receptron, Inc. (USA)

34. Regeneron Pharmaceuticals, Inc. (USA)

35. Sankyo Pharma, Inc. (USA)

36. Santa Cruz Biotechnology, Inc. (USA)

37. SCIL Proteins GmbH (Germany)

38. Selective Genetics (USA)

39. Sigma-Aldrich Corporation (USA)

Table 75: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)

Table 76: Half Yearly Sales Analysis by Business Unit: 2004-2005 (H1) (In US$ million)

Table 77: Annual Sales Analysis: 2003-2004 (In US$ million)

Table 78: Annual Sales Analysis by Business Unit: 2003-2004 (In US$ million)

Table 79: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million)

Table 80: Quarterly Sales Analysis: 2003-2004 (In US$ million)

40. Theratechnologies, Inc. (Canada)

Table 81: Half Yearly Sales Analysis: 2003-2004 (H1) (In CAN$ million)

Table 82: Annual Sales Analysis: 2003-2004 (In CAN$ million)

41. Wockhardt Ltd. (India)

Table 83: Half Yearly Sales Analysis: 2004-2005 (H1) (In INR billion)

Table 84: Annual Sales Analysis: 2003-2004 (In INR billion)

Table 85: Annual Sales Analysis by Segment: 2003-2004 (In INR billion)

Table 86: Annual Sales Analysis by Geographical Region: 2003-2004 (In INR billion)

42. Xcellentis NV (Belgium)

43. Zymogenetics, Inc. (USA)

Abstract

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.